Gary has served as Erasca’s Chief Business Officer since helping launch the company in 2018. He brings more than 20 years of experience in life science operations, finance, business development, IT and program leadership. Prior to Erasca, Gary helped build two biotech companies: Guardant Health and Annexon Biosciences. At Guardant, he was Vice President of the early cancer detection business unit and a member of the leadership team that prepared the company for its initial public offering in 2018. At Annexon, Gary served as Vice President of Business and Development Operations, building the infrastructure to advance drug candidates to clinical development. Gary also held leadership roles with Genentech for 13 years, building organizations across multiple disciplines to develop and launch innovative therapies. He oversaw the portfolio and program management functions that produced 42 INDs and developed multiple FDA-approved treatments, including Tecentriq (anti-PD-L1) and Venclexta (Bcl-2 inhibitor). He also led finance and commercial planning teams as finance leader for the Immunology Business Unit and head of business planning for the Oncology Business Unit to support the launch and expansion of the drugs Avastin, Tarceva, Rituxan and Herceptin. Gary also currently serves as a Venture Partner with LYZZ Capital. Earlier in his career, Gary was a management consultant with McKinsey & Company and operational leader with General Electric. Gary holds a B.S. in Chemical Engineering from University of California, Berkeley and an MBA from University of California, Los Angeles. He is a Chartered Financial Analyst (CFA) and Certified Project Management Professional (PMP).